Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Puma Biotechnology (PBYI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,621,980
  • Shares Outstanding, K 38,030
  • Annual Sales, $ 27,690 K
  • Annual Income, $ -291,960 K
  • 36-Month Beta -0.10
  • Price/Sales 61.90
  • Price/Cash Flow N/A
  • Price/Book 42.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.09
  • Number of Estimates 2
  • High Estimate -1.06
  • Low Estimate -1.11
  • Prior Year -2.07
  • Growth Rate Est. (year over year) +47.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.30 +1.45%
on 08/13/18
54.20 -22.69%
on 08/10/18
-10.60 (-20.19%)
since 07/17/18
3-Month
41.30 +1.45%
on 08/13/18
65.45 -35.98%
on 06/26/18
-12.15 (-22.48%)
since 05/17/18
52-Week
41.30 +1.45%
on 08/13/18
136.90 -69.39%
on 11/08/17
-38.80 (-48.08%)
since 08/17/17

Most Recent Stories

More News
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

ILMN : 325.88 (-0.34%)
PBYI : 41.90 (-1.76%)
GILD : 72.92 (-3.53%)
RHHBY : 30.1200 (+0.57%)
Today's Research Reports on Trending Tickers: Puma Biotechnology and Corcept Therapeutics

NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with...

PBYI : 41.90 (-1.76%)
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 53.17% and 0.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

PBYI : 41.90 (-1.76%)
Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More

Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.

BDSI : 2.85 (+1.79%)
PBYI : 41.90 (-1.76%)
LOXO : 158.34 (-0.13%)
PRGO : 72.96 (+3.64%)
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?

On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.

ACIU : 8.56 (-2.28%)
BDSI : 2.85 (+1.79%)
PBYI : 41.90 (-1.76%)
DNLI : 15.74 (-2.66%)
Puma Biotechnology Files New Drug Submission for NERLYNX(R) in Canada

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for the medicinal product...

PBYI : 41.90 (-1.76%)
Excelera(R) Specialty Pharmacy Network Announces Access to Breast Cancer Treatment NERLYNX™ for Health System-based Specialty Pharmacies

Puma Biotechnology, Inc. and ExceleraRx(R) Corp. have entered into a definitive agreement whereby NERLYNX (neratinib) will be made available through Excelera to health system specialty pharmacies for the...

PBYI : 41.90 (-1.76%)
After Yesterday's Decline of 1.21%, Puma Biotechnolo Offers Investors Better Value

Puma Biotechnolo (NASDAQ:PBYI) traded in a range yesterday that spanned from a low of $56.50 to a high of $58.50. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of...

PBYI : 41.90 (-1.76%)
Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX(R) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that on June 28, 2018 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation...

PBYI : 41.90 (-1.76%)
August 10th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the August 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain...

PBYI : 41.90 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PBYI with:

Business Summary

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth...

See More

Key Turning Points

2nd Resistance Point 43.40
1st Resistance Point 42.65
Last Price 41.90
1st Support Level 41.35
2nd Support Level 40.80

See More

52-Week High 136.90
Fibonacci 61.8% 100.38
Fibonacci 50% 89.10
Fibonacci 38.2% 77.82
Last Price 41.90
52-Week Low 41.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar